51632-06-5

Usage

InChI:InChI=1/C10H12O/c11-7-8-4-5-9-2-1-3-10(9)6-8/h4-6,11H,1-3,7H2

Upstream product

• 2396-63-6 hepta-1,6-diyne 
• 107-19-7 propargyl alcohol 
• 50-00-0 formaldehyd 
• 496-11-7 INDANE 
• 65898-38-6 indan-5-carboxylic acid 
• 113364-54-8 1-(2-indan-5-yl-2-oxo-ethyl)-pyridinium; iodide 
• 4228-10-8 1-indan-5-yl-ethanone 
• 6134-54-9 5-bromoindane 
• 24425-40-9 indan-5-amine 
• 30084-91-4 indan-5-carbaldehyde 
• 86031-43-8 methyl 5-indanecarboxylate 
• 105640-11-7 Indancarbonsaeure-(5)-ethylester 

Downstream Products

• 51629-71-1 3-Methyl-2-p-tolyl-butyric acid indan-5-ylmethyl ester 
• 18775-42-3 5-chloromethylindane 
• 30084-91-4 indan-5-carbaldehyde 
• 13203-56-0 indan-5-ylmethylamine 
• 1187212-05-0 4-(indan-5-ylmethoxy)benzaldehyde 
• 18775-43-4 (5-indanyl)acetonitrile 
• 56635-88-2 3t-(indanyl-⁽⁵⁾)-acrylic acid 
• 65898-38-6 indan-5-carboxylic acid 
• 23291-98-7 3-(2.3-Dihydro-1H-inden-5-yl)-propanoic acid 
• 56635-88-2 3-(5-Indanyl)-prop-2-ensaeure 
• 14927-65-2 3,6,7,8-tetrahydro-2H-as-indacen-1-one 
• 14927-64-1 3,5,6,7-tetrahydro-2H-s-indacen-1-one 
• 495-52-3 s-hydrindacene 
• 501649-52-1 5-(bromomethyl)-2,3-dihydro-1H-indene 

Relevant academic research and scientific papers

Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype

As universal heterodimer partners of many nuclear receptors, the retinoid X receptors (RXRs) constitute key transcription factors. They regulate cell proliferation, differentiation, inflammation, and metabolic homeostasis and have recently been proposed as potential drug targets for neurodegenerative and inflammatory diseases. Owing to the hydrophobic nature of RXR ligand binding sites, available synthetic RXR ligands are lipophilic, and their structural diversity is limited. Here, we disclose the computer-assisted discovery of a novel RXR agonist chemotype and its systematic optimization toward potent RXR modulators. We have developed a nanomolar RXR agonist with high selectivity among nuclear receptors and superior physicochemical properties compared to classical rexinoids that appears suitable for in vivo applications and as lead for future RXR-targeting medicinal chemistry.

Discovery of Benzocycloalkane Derivatives Efficiently Blocking Bacterial Virulence for the Treatment of Methicillin-Resistant S. aureus (MRSA) Infections by Targeting Diapophytoene Desaturase (CrtN)

Antivirulence strategies are now attracting interest for the inherent mechanism of action advantages. In our previous work, diapophytoene desaturase (CrtN) was identified to be an attractive and drugable target for fighting pigmented S. aureus infections. In this research, we developed a series of effective benzocycloalkane-derived CrtN inhibitors with submicromolar IC50. Analogue 8 blocked the pigment biosynthesis of three MRSA strains with a nanomolar IC50 value. Corresponding to its mode of action, 8 did not function as a bactericidal agent. 8 could sensitize S. aureus to immune clearance. In vivo, 8 was proven to be efficacious in an S. aureus Newman sepsis model and abscess formation model. For two typical MRSAs, USA400 MW2 and Mu50, 8 significantly decreased the staphylococcal loads in the liver and kidneys. Moreover, 8 showed minimal antifungal activity compared to that of NTF. In summary, 8 has the potential to be developed as a therapeutic drug, especially against intractable MRSA issues.

Chiral N-phosphino sulfinamide ligands in rhodium(I)-catalyzed [2+2+2] cycloaddition reactions

The combination of cationic rhodium(I) complexes with N-phosphino tert-butylsulfinamides (PNSO) ligands is efficient for catalytic intra- and intermolecular [2+2+2] cycloaddition reactions. PNSO ligands are a new class of chiral bidentate ligands, which h

NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS

The present invention relates to the novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, to process and intermediates for the preparation of the above said compounds, having the utility of these compounds in medicine and to methods for their therapeutic use, and their use in the treatment of metabolic disorders.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, L2, M, X, L3, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Two classes of p38α MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes

Two new classes of diphenylether inhibitors of p38α MAP kinase are described. Both chemical classes are based on a common diphenylether core that is identified by simulated fragment annealing as one of the most favored chemotypes within a prominent hydrophobic pocket of the p38α ATP-binding site. In the fully elaborated molecules, the diphenylether moiety acts as an anchor occupying the deep pocket, while polar extensions make specific interactions with either the adenine binding site or the phosphate binding site of ATP. The synthesis, crystallographic analysis, and biological activity of these p38α inhibitors are discussed.

SYNTHESIS OF TRICYCLIC BENZAZEPINES AND THEIR DOPAMINE D1- AND D2-AFFINITY

A new group of angular 8,9-annelated 3-benzazepines has been found to be potent and selective dopamine D1-receptor antagonists of interest as possible pharmaceuticals in the treatment of schizophrenia.The synthesis of three new conformationally constrained representatives of this group of benzazepines is described and their affinity to the D1-receptor evaluated.Although none of these proved superior to the previously examined compounds, useful information on the receptor binding site was obtained.

Rhodium-catalysed -Cycloadditions of Acteylenes

Wilkinson's catalyst (0.5-2 molpercent) catalyses the chemospecific -cycloaddition of hepta-1,6-diynes with monoynes to give polysubstituted benzene derivatives in moderate to good yield.The reaction is favoured by polar solvents such as ethanol and occurs at 0-78 deg C.Several examples of intramolecular -cycloadditions of triynes are described and a mechanism that accounts for the chemospecificty and observed variations in rates of reaction is discussed.

Aromatic Spiranes, XIV: Syntheses of 2,2'-Spirobi-(s-hydrindacene) and its precursors

The title compound 35 was prepared by catalytic reduction of the diones 29a and 11a. 29a was synthesized by systematic anellation of fivemembered rings to the positions 5,6 and 5',6', resp., of 2,2'-spirobiindane.The preparation of 11a was achieved by Friedel-Crafts cyclisation of bis-(5-indanylmethyl)-malonic acid. s-Hydrindacene-1-one 5a was prepared as a precursor for the synthesis of 11a (see forthcoming publication) and its derivates as models for corresponding anellation and substitution reactions. - Keywords: s-Hydrindacene-1-one and derivates; Mono- and bisanellation; 2,2'-Spirobiindane; 1H-nmr spectra